|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMSP0502AJ03
|
type IV A antigen(d18:1/20:0)
|
GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1794
|
C84H151N3O37
|
|
LMSP0502BN03
|
|
GalNAcbeta1-3(Fucalpha2-3Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1794
|
C84H151N3O37
|
|
LMSP0502BI03
|
|
Fucalpha2-3(Galbeta1-4)GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1794
|
C84H151N3O37
|
|
LMSP0502BJ03
|
|
Galbeta1-3(Fucalpha2-3GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502]
|
1794
|
C84H151N3O37
|
|
LMSP0503AH03
|
|
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1794
|
C84H151N3O37
|
|
LMSP0503AL03
|
|
GalNAcbeta1-3Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) [SP0503]
|
1794
|
C84H151N3O37
|
|
LMSP0504AN03
|
|
Fucalpha1-2Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1794
|
C84H151N3O37
|
|
LMSP0504AV03
|
|
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1794
|
C84H151N3O37
|
|
LMSP0504BD03
|
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1794
|
C84H151N3O37
|
|
LMSP0504AM03
|
|
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) [SP0504]
|
1794
|
C84H151N3O37
|
|
LMSP0505AS03
|
Lex-7(d18:1/20:0)
|
Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|
|
LMSP0505AM03
|
type II H antigen(d18:1/20:0)
|
Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|
|
LMSP0505CK03
|
|
Galbeta1-3GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|
|
LMSP0505CI03
|
|
Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|
|
LMSP0505AV03
|
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|
|
LMSP0505AH03
|
|
Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
|
Neutral glycosphingolipids [SP05]
|
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) [SP0505]
|
1794
|
C84H151N3O37
|